Access
To read this story in full you will need to login or make a payment (see right).
Brief Communications Arising
Nature 443, E6-E7 (21 September 2006) | doi:10.1038/nature05220; Published online 20 September 2006
Open Innovation Challenges
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
- More Challenges
- Powered by:
nature jobs
Scientist (Bioinformatics)
- Polyclone Bioservices Pvt. Ltd
- Bangalore India
Assoc. Scientific Manager / Scientific Manager - Biopharmaceutics
- Syngene International
- Bangalore, Karnataka 560099 India
Gene therapy: Is IL2RG oncogenic in T-cell development?: X-SCID transgene leukaemogenicity (reply)
Niels-Bjarne Woods1, Virginie Bottero1, Manfred Schmidt2, Christof von Kalle2 & Inder M. Verma1
Abstract
Using a lentiviral vector and a murine model of X-linked severe combined immune deficiency (X-SCID), we have shown that mice transplanted with cells constitutively overexpressing the therapeutic gene IL2RG, a subunit found in several cytokine receptors, can develop thymic lymphomas 6 to 12 months later1. Our results contradict those of Pike-Overzet et al 2and Thrasher et al.3.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16Leukemia Original Article
Gene therapy X-SCID transgene leukaemogenicityNature Brief Communication (21 Sep 2006)
See all 14 matches for Research